Web of Pharma · Equipment Qualification
Design Qualification of Pharmaceutical Equipment
A practical, risk-based guide to confirming that an equipment design is suitable for its intended GMP use before installation and operational testing begin.
Quick answer: What is design qualification?
Design Qualification (DQ) is the documented review that demonstrates a proposed facility, utility, system, or equipment design is suitable for its intended purpose and applicable GMP needs. For equipment, DQ checks the approved user requirements against drawings, specifications, materials, operating capabilities, cleaning and maintenance provisions, controls, and relevant risks—before the design is accepted for installation and later qualification.
What is Design Qualification (DQ) for pharmaceutical equipment?
Design Qualification is a planned and recorded assessment of whether the selected design can meet the equipment’s intended use and applicable quality requirements. It is performed while design choices can still be corrected economically—typically after the user needs and design proposal are sufficiently defined, and before the equipment is installed and released for routine operation.
DQ is not merely signing a supplier drawing or confirming that a machine has been delivered. Reviewers assess whether the proposed design addresses the approved User Requirement Specification (URS), process knowledge, contamination-control needs, cleanability, maintainability, safety, and data or automation risks. The depth of review depends on the equipment’s complexity and potential impact.
For example, a simple non-product-contact trolley may need a focused documented assessment, while a product-contact reactor with automated temperature control, recipe management, electronic records, and clean-in-place functions usually needs a broader multidisciplinary review.
GMP and regulatory context for equipment DQ
EU GMP Annex 15 describes DQ as the documented demonstration that the proposed design of equipment, facilities, or systems is suitable for its intended purpose and compliant with GMP. It also states that URS requirements should be verified during DQ. The Annex presents qualification as a lifecycle activity from initial user requirements through the end of use, with stages adapted to the individual project. Read EU GMP Annex 15.
In the United States, FDA drug CGMP regulations focus on outcomes such as equipment being appropriately designed, of suitable size and location, constructed from appropriate materials, and maintained and cleaned. FDA’s equipment Q&A explains that firms select equipment for their intended operations and highlights 21 CFR 211.63, 211.65, 211.67, and 211.68. It does not prescribe a single universal DQ template. See FDA’s equipment CGMP Q&A.
Quality risk management helps determine which design characteristics require deeper review or stronger verification. ICH Q9(R1) links risk evaluation to scientific knowledge and patient protection, and says the level of formality and documentation should be commensurate with risk. It does not replace regulatory obligations. See ICH Q9(R1).
Where DQ fits in the equipment qualification lifecycle
DQ connects user needs to the design evidence and subsequent qualification work. It helps ensure that important requirements are not discovered for the first time during site testing.
| Stage | Main question | Typical DQ connection |
|---|---|---|
| URS / functional requirements | What must the equipment do, and under what conditions? | Establishes the approved baseline for design review. |
| Supplier design and specifications | How will the proposed design meet the stated needs? | Compare functional descriptions, drawings, materials, control design, and interfaces to requirements. |
| Design Qualification | Is the proposed design suitable and are GMP risks addressed? | Record review, gap resolution, rationale, and approval before design freeze or installation. |
| FAT / SAT | Does the built equipment match the reviewed design and selected functions? | May verify design-dependent functions at the supplier or site when justified. |
| IQ | Was equipment installed as approved? | Confirms installed components, utilities, instruments, and documents against approved design. |
| OQ | Does it operate as intended across specified ranges? | Challenges functions, limits, alarms, and relevant worst cases. |
| PQ | Can equipment perform effectively and reproducibly in the process? | Confirms process-related performance under defined operating conditions. |
Some verification can occur at the supplier through factory acceptance testing. Annex 15 allows suitable tests or document reviews to be leveraged rather than repeated at the site when justified and when transport or installation does not affect the function. The site must document its rationale and still complete site-specific verification.
What should a DQ review cover?
Build the review around the approved requirements and risk assessment rather than using a generic checklist as a substitute for engineering judgment. Depending on the equipment, DQ may evaluate:
- Intended use and process fit: capacity, operating range, throughput, process sequence, product characteristics, and interfaces.
- Product-contact design: construction materials, compatibility, surface finish where relevant, seals, joints, and risk of shedding, reaction, adsorption, or contamination.
- Cleaning and contamination control: access, drainability, dead spaces, removable parts, clean-in-place coverage, containment, and cross-contamination controls.
- Instrumentation and control: sensors, ranges, accuracy, control loops, interlocks, alarms, recipes, overrides, and failure states.
- Automation and records: user access, data capture, time stamps, audit trail needs, interfaces, backup, and retention when GMP records are created or used.
- Utilities and facility interfaces: electrical power, compressed gases, water, steam, exhaust, network connections, HVAC, floor loading, and spatial/access needs.
- Maintainability and calibration: service access, maintainable parts, calibration points, maintenance intervals, spare parts, and supplier support.
- Safety and ergonomics: guarding, pressure or temperature hazards, lifting, noise, operator access, and applicable site safety requirements.
- Documentation and training: drawings, manuals, certificates, software/configuration information, recommended maintenance, and training deliverables.
Equipment intended for sterile processing, potent compounds, biologics, or other specialized operations may require additional controls. These should be based on the process-specific contamination, product-quality, and personnel risks rather than copied from an unrelated project.
How to perform Design Qualification step by step
Confirm the DQ scope and design baseline
Identify the equipment tag, project boundary, intended use, approved URS revision, supplier design package, applicable drawings, functional specifications, and related systems. Record exclusions and interfaces.
Establish review criteria and responsibilities
Define the documents to review, required subject-matter experts, risk-ranking approach, acceptance criteria, and how comments, deviations, and approval will be managed. QA, engineering, users, validation, maintenance, and automation may all contribute.
Perform risk-based design review
Evaluate whether the design can meet each applicable requirement and whether failure could affect product quality, patient safety, data integrity, cleaning, or process control. Use a proportionate risk method, documenting assumptions and controls.
Trace each requirement to design evidence
Link URS identifiers to drawings, datasheets, calculations, material specifications, control narratives, software descriptions, supplier evidence, or planned tests. Mark each as met, partially met, not met, not applicable with rationale, or pending resolution.
Resolve gaps before approval
Correct design gaps or document a technically justified alternative that still meets the requirement. A change in user need should be processed through controlled URS change management; a design deviation should have an owner, impact assessment, and closure evidence.
Plan verification across FAT, SAT, IQ, OQ, and PQ
Assign each requirement an appropriate verification stage and test method. Avoid testing the same feature repeatedly without a reason, but do not rely on a supplier test when site conditions could change the result.
Approve the DQ conclusion and control the package
Summarize the outcome, open actions, residual risks, and readiness to proceed. Obtain approval from authorized functions and retain the report, matrix, reviewed design records, and linked change/deviation records in the controlled project file.
Example DQ review matrix for a pharmaceutical mixer
The following example is illustrative. Actual acceptance criteria must be defined from the process, product, equipment design, and site requirements.
| URS ID | Design evidence reviewed | DQ question / acceptance basis | Follow-up verification |
|---|---|---|---|
| URS-PER-001 | Vessel datasheet and general arrangement drawing | Does the working volume cover the approved batch range with appropriate headspace? | Vendor test or site volume/functional check, as assigned |
| URS-MAT-001 | Product-contact material list and certificates | Are materials identified and suitable for the product and cleaning agents? | IQ material verification and document review |
| URS-CLN-001 | Vessel cross-section, spray device layout, drain detail | Are product-contact surfaces accessible and the proposed cleaning approach technically plausible? | Cleaning coverage testing or cleaning qualification as applicable |
| URS-CTL-001 | Control narrative, I/O list, alarm list | Are speed limits, permissives, alarms, and safe states defined and consistent with process needs? | OQ challenge tests |
| URS-DAT-001 | Automation architecture and record/recipe description | Are GMP-relevant data, access roles, and record-review needs accounted for? | Computerized-system assessment and applicable tests |
| URS-MNT-001 | Maintenance access drawing and supplier manual outline | Can critical components be inspected, serviced, and calibrated without unacceptable contamination or safety risks? | IQ checks, maintenance plan review, and handover |
DQ should not mark a requirement “pass” solely because a supplier states that the feature is standard. The reviewer should identify objective design evidence or specify how the feature will be verified later.
DQ protocol, evidence, and report: what to retain
A controlled DQ package commonly contains the following, scaled to the project:
- Approved DQ protocol or documented review plan, scope, responsibilities, criteria, and document list.
- Current approved URS and functional requirements, including revision history.
- Supplier design records reviewed: drawings, specifications, materials, calculations, control descriptions, and interface information as relevant.
- Requirement-to-design traceability matrix with clear status, evidence references, and review comments.
- Quality risk assessment and rationale for the extent of DQ and later verification.
- Documented deviations, design gaps, decisions, change controls, and action closure evidence.
- DQ summary report, conclusion, approval, and authorization or recommendation to proceed to the next stage.
Annex 15 expects qualification work to be planned, reviewed, and reported against predefined acceptance criteria; results that fail criteria should be documented and investigated. Maintain accurate, attributable records consistent with site data-integrity practices and ALCOA+ principles.
Common DQ mistakes and how to avoid them
- Starting after design freeze: perform the review early enough for findings to influence the design and procurement decision.
- Checking documents without checking requirements: use a requirement-by-requirement matrix to prevent important needs from disappearing in a broad drawing review.
- Accepting vague supplier assurances: require objective evidence or schedule a defined test for critical functions.
- Confusing DQ with FAT or OQ: DQ assesses design suitability; FAT/OQ test selected functions. They may share evidence, but their objectives differ.
- Ignoring cleaning, maintenance, or operator access: include operations, cleaning, and maintenance experts in design review.
- Using risk scores mechanically: explain the harm, controls, assumptions, and residual risk; a number alone does not justify scope.
- Leaving unresolved gaps hidden in the report: assign each action, assess its impact, and document closure or a justified disposition.
- Repeating the same tests unnecessarily: leverage supplier evidence only after documented assessment of test suitability, controls, and transport/installation impact.
If DQ uncovers a significant design gap, assess whether the approved requirements, product or process risk, procurement, or project timeline is affected. Manage corrective actions through the site quality system and CAPA where warranted.
DQ in a wider pharmaceutical qualification program
DQ is one part of the equipment validation lifecycle. It helps teams establish that the proposed design is appropriate before installation. It does not by itself prove that the equipment was installed correctly, operates throughout its intended range, or performs consistently in the process. Those questions are addressed through the approved IQ, OQ, and PQ strategy.
For assets with control systems or GMP electronic records, include automation and data requirements in the design review and link to the site’s Computerized System Validation lifecycle. Equipment used in a validated process should also align with the site’s Process Validation strategy and controlled SOPs.
Frequently asked questions
1. What is Design Qualification in pharmaceutical equipment?
Design Qualification is the documented demonstration that a proposed equipment design is suitable for its intended purpose and applicable GMP needs. It verifies relevant user requirements against design evidence and identifies unresolved gaps before installation and later qualification.
2. Is DQ the same as design review?
DQ is a controlled, documented qualification activity. A general design review may contribute evidence, but it becomes an adequate DQ record only when its scope, criteria, requirement traceability, findings, rationale, and approvals meet the site’s approved procedure.
3. When should DQ be performed?
Perform DQ after sufficient user and design information is available and early enough to resolve design issues before installation or design freeze makes changes difficult. The precise timing depends on the project and its quality risks.
4. Is DQ mandatory for all pharmaceutical equipment?
Requirements vary by jurisdiction and quality system. EU GMP Annex 15 identifies DQ as a qualification stage for equipment, facilities, utilities, and systems. Other frameworks may focus on equipment suitability and documented controls without prescribing one universal DQ format. Follow applicable requirements and site procedures.
5. What is the difference between URS and DQ?
The URS records what the user needs the equipment to do. DQ checks whether the proposed design can meet those needs and applicable GMP requirements. The URS is an input and reference for DQ.
6. What documents are reviewed during DQ?
Depending on the asset, reviewers may assess the approved URS, functional specification, drawings, equipment datasheets, material lists, control narratives, calculations, risk assessments, supplier documents, cleaning concepts, and utility or facility interfaces.
7. What is the difference between DQ and FAT?
DQ evaluates whether the design is suitable and meets requirements. FAT is testing or inspection at the supplier’s facility to verify selected functions or build characteristics. FAT evidence can support DQ or later qualification when its suitability is assessed and documented.
8. Can a supplier perform DQ?
A supplier can provide design evidence and support the review, but the user organization should assess the equipment against its own intended use, GMP risks, and approved requirements. The site remains responsible for review, suitability, and approval under its quality system.
9. Does DQ replace IQ, OQ, or PQ?
No. DQ evaluates the proposed design. IQ checks installation, OQ checks operation within defined ranges, and PQ checks performance in the intended process context. The qualification plan can leverage suitable evidence, but each relevant objective must be addressed.
10. What happens if a DQ requirement is not met?
Document the gap, assess its impact on product quality, safety, compliance, and downstream qualification, then assign a corrective action or justified disposition. Update controlled requirements or design records through change control when needed, and close the action before release to the next stage unless a documented, approved rationale permits otherwise.
Conclusion
Design Qualification gives pharmaceutical teams an early, structured way to verify that equipment design matches approved user needs and applicable GMP expectations. A sound DQ is risk-based, multidisciplinary, traceable to the URS, supported by objective design evidence, and clear about open items. Done well, it reduces late engineering changes and gives IQ, OQ, and PQ a reliable design baseline.
This article is an educational overview, not a substitute for applicable regulations, current guidance, site procedures, or a project-specific quality risk assessment.
References
- European Commission, EudraLex Volume 4, Annex 15: Qualification and Validation.
- European Commission, EudraLex Volume 4 index (Annex 15 operational since 1 October 2015).
- U.S. FDA, Questions and Answers on Current Good Manufacturing Practice Requirements: Equipment.
- ICH Q9(R1), Quality Risk Management.
.webp)
